<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00689351</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-010</org_study_id>
    <secondary_id>B1851001</secondary_id>
    <nct_id>NCT00689351</nct_id>
  </id_info>
  <brief_title>Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea</brief_title>
  <official_title>Phase 2, Randomized, Active-Controlled, Double-Blind Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Healthy Infants Given With Routine Pediatric Vaccinations In Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and immunogenicity of a
      13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal
      conjugate vaccine (7vPnC) when given concomitantly with routine vaccines in Korea.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After the Infant Series</measure>
    <time_frame>1 month after the infant series (7 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.35 Mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) was calculated for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Serotype-specific IgG Antibody Level ≥0.35 Mcg/mL Measured 1 Month After the Toddler Dose</measure>
    <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
    <description>Percentage of participants achieving predefined antibody threshold ≥0.35Mcg/mL along with the corresponding 95% CI was calculated for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A). Exact 2-sided CI was based on the observed percentage of participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Pneumococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>13vPnC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7vPnC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>7-valent pneumococcal conjugate vaccine</intervention_name>
    <description>7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy 2-month-old-infants (42 to 98 days)

          -  Available for the entire study period (14 months)

        Exclusion Criteria:

          -  Previous vaccine with pneumococcal, diptheria, tetanus, pertussis, polio or Hib
             vaccine

          -  A previous severe reaction to any vaccine or vaccine-related component
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>98 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Incheon</city>
        <state>Bupyeong-gu</state>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Incheon</city>
        <state>Jung-gu</state>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyunggi</city>
        <state>Koyang</state>
        <zip>412-270</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seoul</city>
        <state>Yeongdeungpo-gu</state>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6096A1-010&amp;StudyName=Study%20Evaluating%20A%2013-Valent%20Pneumococcal%20Conjugate%20Vaccine%20Administered%20To%20Infants%20In%20Korea</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>December 10, 2010</results_first_submitted>
  <results_first_submitted_qc>December 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 11, 2011</results_first_posted>
  <last_update_submitted>June 24, 2011</last_update_submitted>
  <last_update_submitted_qc>June 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Wyeth, Inc</organization>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>against</keyword>
  <keyword>pneumococcal</keyword>
  <keyword>disease</keyword>
  <keyword>Vaccine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="P2">
          <title>7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Infant Series of Dosing</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent/legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>After Infant Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent/legal guardian request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Toddler Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B2">
          <title>7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" spread="0.3"/>
                    <measurement group_id="B2" value="2.1" spread="0.2"/>
                    <measurement group_id="B3" value="2.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After the Infant Series</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.35 Mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) was calculated for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A).</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable Infant Immunogenicity population: participants who were 41 to 99 days of age (inclusive) on the day of the first vaccination, who had treatments as randomized (all expected doses) and at least 1 valid and determinate assay result for proposed analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Serotype-specific Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After the Infant Series</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.35 Mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) was calculated for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A).</description>
          <population>Evaluable Infant Immunogenicity population: participants who were 41 to 99 days of age (inclusive) on the day of the first vaccination, who had treatments as randomized (all expected doses) and at least 1 valid and determinate assay result for proposed analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91.6" upper_limit="99.7"/>
                    <measurement group_id="O2" value="98.8" lower_limit="93.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.8" lower_limit="93.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.3" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.3" upper_limit="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="57.5" lower_limit="45.9" upper_limit="68.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91.6" upper_limit="99.7"/>
                    <measurement group_id="O2" value="72.3" lower_limit="61.4" upper_limit="81.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="4.8" lower_limit="1.3" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Serotype-specific IgG Antibody Level ≥0.35 Mcg/mL Measured 1 Month After the Toddler Dose</title>
        <description>Percentage of participants achieving predefined antibody threshold ≥0.35Mcg/mL along with the corresponding 95% CI was calculated for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A). Exact 2-sided CI was based on the observed percentage of participants.</description>
        <time_frame>1 month after the toddler dose (13 months of age)</time_frame>
        <population>Evaluable Toddler Immunogenicity population:41-99 days old inclusive on day of first vaccination, 365-395 days old inclusive at toddler dose, had all treatments as randomized, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Serotype-specific IgG Antibody Level ≥0.35 Mcg/mL Measured 1 Month After the Toddler Dose</title>
          <description>Percentage of participants achieving predefined antibody threshold ≥0.35Mcg/mL along with the corresponding 95% CI was calculated for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A). Exact 2-sided CI was based on the observed percentage of participants.</description>
          <population>Evaluable Toddler Immunogenicity population:41-99 days old inclusive on day of first vaccination, 365-395 days old inclusive at toddler dose, had all treatments as randomized, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7" lower_limit="93.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="1.3" lower_limit="0.0" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="12.0" lower_limit="5.9" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="92.4" lower_limit="84.2" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" lower_limit="93.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="95.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="23.6" lower_limit="13.2" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="95.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="98.8" lower_limit="93.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) of Serotype-specific IgG Antibody 1 Month After the Infant Series</title>
        <description>Antibody GMC along with corresponding 2-sided 95% CI for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Geometric mean concentrations (GMCs) were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after the infant series (7 months of age)</time_frame>
        <population>Evaluable Infant Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serotype-specific IgG Antibody 1 Month After the Infant Series</title>
          <description>Antibody GMC along with corresponding 2-sided 95% CI for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Geometric mean concentrations (GMCs) were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable Infant Immunogenicity Population</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" lower_limit="4.62" upper_limit="6.30"/>
                    <measurement group_id="O2" value="6.97" lower_limit="5.94" upper_limit="8.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" lower_limit="4.64" upper_limit="7.03"/>
                    <measurement group_id="O2" value="4.88" lower_limit="3.96" upper_limit="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.90" upper_limit="3.83"/>
                    <measurement group_id="O2" value="3.78" lower_limit="3.31" upper_limit="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.83" lower_limit="12.38" upper_limit="17.77"/>
                    <measurement group_id="O2" value="16.29" lower_limit="13.36" upper_limit="19.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.57" lower_limit="3.98" upper_limit="5.24"/>
                    <measurement group_id="O2" value="4.73" lower_limit="4.09" upper_limit="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.18" upper_limit="4.72"/>
                    <measurement group_id="O2" value="4.20" lower_limit="3.55" upper_limit="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" lower_limit="3.56" upper_limit="5.16"/>
                    <measurement group_id="O2" value="4.11" lower_limit="3.40" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.44" lower_limit="6.25" upper_limit="8.85"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.02" upper_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.35" upper_limit="1.89"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" lower_limit="4.37" upper_limit="5.85"/>
                    <measurement group_id="O2" value="0.39" lower_limit="0.30" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.73" lower_limit="4.64" upper_limit="7.07"/>
                    <measurement group_id="O2" value="0.64" lower_limit="0.49" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.97" lower_limit="6.07" upper_limit="8.00"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" lower_limit="5.13" upper_limit="6.89"/>
                    <measurement group_id="O2" value="2.65" lower_limit="2.29" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>329.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>242.98</ci_lower_limit>
            <ci_upper_limit>446.67</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>40.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.27</ci_lower_limit>
            <ci_upper_limit>54.97</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>13.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.92</ci_lower_limit>
            <ci_upper_limit>17.34</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>9.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.46</ci_lower_limit>
            <ci_upper_limit>12.56</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>165.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>122.95</ci_lower_limit>
            <ci_upper_limit>223.85</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>2.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.83</ci_lower_limit>
            <ci_upper_limit>2.75</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) of Serotype-specific IgG Antibody 1 Month After the Toddler Dose</title>
        <description>Antibody GMC along with corresponding 2-sided 95% CI for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Geometric mean concentrations (GMCs) were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after the Toddler Dose (13 months of age)</time_frame>
        <population>Evaluable Toddler Immunogenicity Population</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serotype-specific IgG Antibody 1 Month After the Toddler Dose</title>
          <description>Antibody GMC along with corresponding 2-sided 95% CI for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Geometric mean concentrations (GMCs) were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable Toddler Immunogenicity Population</population>
          <units>Mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.46" lower_limit="5.29" upper_limit="7.90"/>
                    <measurement group_id="O2" value="8.25" lower_limit="6.88" upper_limit="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.81" lower_limit="14.36" upper_limit="19.68"/>
                    <measurement group_id="O2" value="15.14" lower_limit="11.91" upper_limit="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="3.91" upper_limit="5.38"/>
                    <measurement group_id="O2" value="4.83" lower_limit="4.12" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.51" lower_limit="9.59" upper_limit="13.80"/>
                    <measurement group_id="O2" value="15.64" lower_limit="13.07" upper_limit="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" lower_limit="5.67" upper_limit="8.29"/>
                    <measurement group_id="O2" value="7.44" lower_limit="6.27" upper_limit="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" lower_limit="6.30" upper_limit="9.53"/>
                    <measurement group_id="O2" value="5.35" lower_limit="4.52" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.95" lower_limit="8.77" upper_limit="13.66"/>
                    <measurement group_id="O2" value="10.44" lower_limit="8.60" upper_limit="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" lower_limit="7.65" upper_limit="11.28"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.40" upper_limit="1.95"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.08" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" lower_limit="7.62" upper_limit="10.45"/>
                    <measurement group_id="O2" value="1.31" lower_limit="1.09" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.58" lower_limit="11.28" upper_limit="16.36"/>
                    <measurement group_id="O2" value="3.33" lower_limit="2.67" upper_limit="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.17" lower_limit="9.33" upper_limit="13.37"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.07" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.12" lower_limit="8.55" upper_limit="11.98"/>
                    <measurement group_id="O2" value="2.38" lower_limit="2.04" upper_limit="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 4: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6B: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 9V: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 14: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 18C: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19F: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.88</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 23F: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 1: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>234.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>176.33</ci_lower_limit>
            <ci_upper_limit>311.41</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 3: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>16.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.19</ci_lower_limit>
            <ci_upper_limit>22.69</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 5: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>6.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.39</ci_lower_limit>
            <ci_upper_limit>8.67</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 6A: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>4.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.07</ci_lower_limit>
            <ci_upper_limit>5.43</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 7F: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>110.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.09</ci_lower_limit>
            <ci_upper_limit>159.59</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serotype 19A: Ratio of geometric means (13vPnC, 7vPnC)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio of geometric means</param_type>
            <param_value>4.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.39</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
            <estimate_desc>CI for the ratio were back transformations of a CI based on the Student t distribution for the mean difference of the logarithms of the measures (13vPnC, 7vPnC).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 1 (2 months of age)</time_frame>
        <population>Safety population: All participants who received at least 1 dose of the study vaccine; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (greater than [&gt;] 7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety population: All participants who received at least 1 dose of the study vaccine; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=23,26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=6,2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=14,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7"/>
                    <measurement group_id="O2" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=8,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6"/>
                    <measurement group_id="O2" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=7,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1"/>
                    <measurement group_id="O2" value="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any (n=27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=23,19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.862</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for significant tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.550</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.366</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.301</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.718</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 2 (4 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=23,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=0,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=22,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=18,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=4,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any (n=20,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=18,24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for significant tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.245</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.447</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.684</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.451</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 3 (6 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=15,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=18,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=13,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=7,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any (n=19,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=12,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=7,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.681</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for significant tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.482</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.683</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.533</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.692</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.331</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)</title>
        <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after toddler dose (12 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)</title>
          <description>Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt;7.0 cm). Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the specific characteristic.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=19,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=3,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=11,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=4,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=9,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any (n=15,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=9,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=8,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for significant tenderness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.617</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.527</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.144</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for severe swelling.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.495</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for any redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.506</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for mild redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for moderate redness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 1 (2 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 degrees C but ≤39 degrees C (n=11,9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=23,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=38,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=37,30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3"/>
                    <measurement group_id="O2" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=28,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8"/>
                    <measurement group_id="O2" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for fever ≥38 degrees C but but less than or equal to (≤)39 degrees C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.633</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased appetite.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.721</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for irritability.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for increased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 2 (4 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 degrees C but ≤39 degrees C (n=6,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=16,28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=25,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.3"/>
                    <measurement group_id="O2" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=17,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=18,27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="40.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for fever ≥38 degrees C but ≤39 degrees C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.781</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased appetite.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for irritability.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.159</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for increased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.839</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after dose 3 (6 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 degrees C but ≤39 degrees C (n=8,5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 degrees C but ≤40 degrees C (n=0,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=14,16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=13,25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=18,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=10,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for fever ≥38 degrees C but ≤39 degrees C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.563</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for fever &gt;39 degrees C but ≤40 degrees C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.468</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased appetite.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.535</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for irritability.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for increased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.398</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)</title>
        <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 4 days after toddler dose (12 months of age)</time_frame>
        <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
          <group group_id="O2">
            <title>7vPnC</title>
            <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)</title>
          <description>Pre-specified systemic events (any fever ≥ 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants reporting the event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 degrees C but ≤39 degrees C (n=7,10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7"/>
                    <measurement group_id="O2" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 degrees C but ≤40 degrees C (n=1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=13,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=18,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=11,8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=11,20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for fever ≥38 degrees C but ≤39 degrees C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.596</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for fever &gt;39 degrees C but ≤40 degrees C.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased appetite.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for irritability.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.439</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for increased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.613</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison between treatments for decreased sleep.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.138</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 1 Month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=2 months of age; Dose 2=4 months of age; Dose 3=6 months of age; Toddler Dose=12 months of age.</time_frame>
      <desc>Safety population = all randomized subjects with at least 1 dose of study treatment. An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Infant Series 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series).</description>
        </group>
        <group group_id="E2">
          <title>Infant Series 7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series).</description>
        </group>
        <group group_id="E3">
          <title>After the Infant Series 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series); assessment 1 month after the infant series (7 months of age).</description>
        </group>
        <group group_id="E4">
          <title>After the Infant Series 7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series); assessment 1 month after the infant series (7 months of age).</description>
        </group>
        <group group_id="E5">
          <title>Toddler Dose 13vPnC</title>
          <description>13-valent pneumococcal conjugate vaccine (13vPnC) 0.5mL dose administered IM at 12 months of age (toddler dose).</description>
        </group>
        <group group_id="E6">
          <title>Toddler Dose 7vPnC</title>
          <description>7-valent pneumococcal conjugate vaccine (7vPnC ) 0.5mL dose administered IM at 12 months of age (toddler dose).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hand-foot-and-mouth disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever 38 degrees C but 39 degrees C</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever 38 degrees C but 39 degrees C</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever ≥ 38 degrees C but ≤ 39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever 38 degrees C but 39 degrees C</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt; 39 degrees C but 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt; 39 degrees C but 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 39 degrees C but ≤ 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt; 39 degrees C but 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Fever &gt; 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Fever &gt; 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever &gt; 40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Fever &gt; 40 degrees C</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="57"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased appetite</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Irritability</description>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="79"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Irritability</description>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Irritability</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Increased sleep</description>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Increased sleep</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Increased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Increased sleep</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Decreased sleep</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Periorbital cellulit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Perineal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Grunting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Heat rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Eczema infantile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; tenderness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="56"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; tenderness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; tenderness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Tenderness (significant)=present and interfered with limb movement</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Tenderness (significant)=present and interfered with limb movement</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness (significant)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Tenderness (significant)=present and interfered with limb movement</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="63"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (any)</sub_title>
                <description>Infant Series Dose 3; Swelling (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Swelling (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Swelling (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Swelling (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (any)=present at site of vaccination.</description>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (any)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (any)=present at site of vaccination</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="61"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (mild)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (mild)=0.5 to 2.0 cm</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (moderate)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (moderate)=2.5 to 7.0 cm</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 1 and Toddler Dose; Redness (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 2; Redness (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness (severe)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Infant Series Dose 3; Redness (severe) &gt;7.0 cm</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer Clinical Trials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquires@Pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

